22 Jul

#NewTrialAnnouncement

PharmaSols is delighted to be working with UNITY Biotechnology, Inc. (UNITY) on their latest ophthalmologic study UBX1325-02, across multiple sites in Australia and New Zealand.

The study is a Phase 2a, Prospective, Multicentre, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Oedema (DME).

UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, nAMD, and DR.

UNITY and PharmaSols look forward to forging a strong on-going relationship. As UNITY expands its global footprint with clinical studies, they are very excited to include AU and NZ in this important effort.

Find out more https://lnkd.in/g_MXh9U

Other News

Directly attributing our success to the quality of our team

Having grown to be one of the leading CROs in Australia and New Zealand, we directly attribute our success to the quality of our team.

Read more
PharmaSols - HiRO announcement

PharmaSols acquired by the newly established global CRO based in Shanghai, HiRO.

Read more
The ANZ Advantage

4 reasons why biotechs need to reconsider running clinical trials in the US – the ANZ advantage

Read more